{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:23:38Z","timestamp":1792103018148,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2016-02364230"],"award-info":[{"award-number":["RF-2016-02364230"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00259-025-07661-w","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T08:21:11Z","timestamp":1764231671000},"page":"3023-3033","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6186-688X","authenticated-orcid":false,"given":"Irene","family":"Marini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5383-4469","authenticated-orcid":false,"given":"Emilio Francesco","family":"Giunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3960-7737","authenticated-orcid":false,"given":"Silvia","family":"Nicolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9566-7670","authenticated-orcid":false,"given":"Ilaria","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5529-4769","authenticated-orcid":false,"given":"Flavia","family":"Foca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5986-3845","authenticated-orcid":false,"given":"Anna","family":"Sarnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5380-6185","authenticated-orcid":false,"given":"Valentina","family":"Di Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7734-3426","authenticated-orcid":false,"given":"Lilla","family":"Vizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Giani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0338-800X","authenticated-orcid":false,"given":"Monica","family":"Celli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3587-1768","authenticated-orcid":false,"given":"Manuela","family":"Monti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1846-0681","authenticated-orcid":false,"given":"Stefano","family":"Severi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7520-2908","authenticated-orcid":false,"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9753-9699","authenticated-orcid":false,"given":"Francesca","family":"Borgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2631-4652","authenticated-orcid":false,"given":"Giovanni","family":"Paganelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7455-6253","authenticated-orcid":false,"given":"Federica","family":"Matteucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7699-262X","authenticated-orcid":false,"given":"Maddalena","family":"Sansovini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"issue":"3","key":"7661_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"7661_CR2","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/GO.20.00511","volume":"7","author":"FC Maluf","year":"2021","unstructured":"Maluf FC, Pereira FMT, Silva AG, et al. Consensus on the treatment and Follow-Up for metastatic Castration-Resistant prostate cancer: A report from the first global prostate cancer consensus conference for developing countries (PCCCDC). JCO Glob Oncol. 2021;7:559\u201371. https:\/\/doi.org\/10.1200\/GO.20.00511.","journal-title":"JCO Glob Oncol"},{"issue":"1","key":"7661_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ajur.2018.11.005","volume":"6","author":"L Dong","year":"2019","unstructured":"Dong L, Zieren RC, Xue W, de Reijke TM, Pienta KJ. Metastatic prostate cancer remains incurable. Why? Asian J Urol. 2019;6(1):26\u201341. https:\/\/doi.org\/10.1016\/j.ajur.2018.11.005.","journal-title":"Asian J Urol"},{"key":"7661_CR4","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630\u201342.","journal-title":"Eur Urol"},{"key":"7661_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00623","volume":"8","author":"MC Hupe","year":"2018","unstructured":"Hupe MC, Philippi C, Roth D, et al. Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis. Front Oncol. 2018;8:623. https:\/\/doi.org\/10.3389\/fonc.2018.00623.","journal-title":"Front Oncol"},{"issue":"4","key":"7661_CR6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/s0090-4295(98)00278-7","volume":"52","author":"SD Sweat","year":"1998","unstructured":"Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52(4):637\u201340. https:\/\/doi.org\/10.1016\/s0090-4295(98)00278-7.","journal-title":"Urology"},{"issue":"1","key":"7661_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/1078-1439(95)00002-y","volume":"1","author":"GL Wright Jr","year":"1995","unstructured":"Wright GL Jr, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995;1(1):18\u201328. https:\/\/doi.org\/10.1016\/1078-1439(95)00002-y.","journal-title":"Urol Oncol"},{"key":"7661_CR8","unstructured":"Gazzetta ufficiale della Repubblica italiana. Agenzia Italiana del Farmaco. Riclassificazione del medicinale per uso umano \u00abPluvicto\u00bb, ai sensi dell\u2019art. 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. 241\/2025). https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2025-03-03&atto.codiceRedazionale=25A01308&elenco30giorni=false"},{"issue":"10","key":"7661_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ph15101292","volume":"15","author":"U Hennrich","year":"2022","unstructured":"Hennrich U, Eder M. [177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer. Pharmaceuticals (Basel). 2022;15(10):1292. https:\/\/doi.org\/10.3390\/ph15101292.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"9","key":"7661_CR10","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","volume":"29","author":"J Fallah","year":"2023","unstructured":"Fallah J, Agrawal S, Gittleman H, et al. FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration- resistant prostate cancer. Clin Cancer Res. 2023;29(9):1651\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2875.","journal-title":"Clin Cancer Res"},{"key":"7661_CR11","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"7","key":"7661_CR12","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/RLU.0000000000001240","volume":"41","author":"K Rahbar","year":"2016","unstructured":"Rahbar K, Bode A, Weckesser M, et al. Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin Nucl Med. 2016;41(7):522\u20138. https:\/\/doi.org\/10.1097\/RLU.0000000000001240.","journal-title":"Clin Nucl Med"},{"issue":"8","key":"7661_CR13","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.2967\/jnumed.115.171397","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Giesel FL, Stefanova M, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med. 2016;57(8):1170\u20136. https:\/\/doi.org\/10.2967\/jnumed.115.171397.","journal-title":"J Nucl Med"},{"issue":"1","key":"7661_CR14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13550-015-0114-2","volume":"5","author":"H Ahmadzadehfar","year":"2015","unstructured":"Ahmadzadehfar H, Rahbar K, K\u00fcrpig S, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015;5(1):114. https:\/\/doi.org\/10.1186\/s13550-015-0114-2.","journal-title":"EJNMMI Res"},{"issue":"7","key":"7661_CR15","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","volume":"57","author":"RP Baum","year":"2016","unstructured":"Baum RP, Kulkarni HR, Schuchardt C, et al. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57(7):1006\u201313. https:\/\/doi.org\/10.2967\/jnumed.115.168443.","journal-title":"J Nucl Med"},{"key":"7661_CR16","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2147\/OTT.S97584","volume":"10","author":"S Severi","year":"2017","unstructured":"Severi S, Grassi I, Nicolini S, Sansovini M, Bongiovanni A, Paganelli G. Peptide receptor radionuclide therapy in the management of Gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life. OncoTargets Ther. 2017;10:551\u20137. https:\/\/doi.org\/10.2147\/OTT.S97584.","journal-title":"OncoTargets Ther"},{"issue":"10","key":"7661_CR17","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s00259-008-0778-1","volume":"35","author":"L Bodei","year":"2008","unstructured":"Bodei L, Cremonesi M, Ferrari M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35(10):1847\u201356. https:\/\/doi.org\/10.1007\/s00259-008-0778-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"7661_CR18","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1007\/s00259-008-0778-1","volume":"125","author":"U De Giorgi","year":"2021","unstructured":"De Giorgi U, Sansovini M, Severi S, et al. Circulating androgen receptor gene amplification and resistance to <\u2009sup\u2009>\u2009177\u2009Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a phase 2 trial. Br J Cancer. 2021;125(9):1226\u201332. https:\/\/doi.org\/10.1007\/s00259-008-0778-1.","journal-title":"Br J Cancer"},{"issue":"3","key":"7661_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/molecules24030621","volume":"24","author":"A Sarnelli","year":"2019","unstructured":"Sarnelli A, Belli ML, Di Iorio V, et al. Dosimetry of <\u2009sup\u2009>\u2009177\u2009Lu-PSMA-617 after mannitol infusion and glutamate tablet administration: preliminary results of EUDRACT\/RSO 2016-002732-32 IRST protocol. Molecules. 2019;24(3):621. https:\/\/doi.org\/10.3390\/molecules24030621.","journal-title":"Molecules"},{"issue":"13","key":"7661_CR20","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1007\/s00259-020-04856-1","volume":"47","author":"G Paganelli","year":"2020","unstructured":"Paganelli G, Sarnelli A, Severi S, et al. Dosimetry and safety of <\u2009sup\u2009>\u2009177\u2009Lu PSMA-617 along with polyglutamate Parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020;47(13):3008\u201317. https:\/\/doi.org\/10.1007\/s00259-020-04856-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7661_CR21","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1200\/JCO.2024.42.16_suppl.5074","volume":"42","author":"S Tagawa","year":"2024","unstructured":"Tagawa S, et al. Final results of a phase I\/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC). JCO. 2024;42:5074\u20135074.","journal-title":"JCO"},{"issue":"6","key":"7661_CR22","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825\u201333. https:\/\/doi.org\/10.1016\/S1470-2045(18)30198-0.","journal-title":"Lancet Oncol"},{"issue":"12","key":"7661_CR23","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Prostate Cancer Clinical Trials Working Group 3, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34(12):1402\u201318. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702.","journal-title":"J Clin Oncol"},{"issue":"12","key":"7661_CR24","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","volume":"46","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Fendler WP, Eiber M, et al. EANM procedure guidelines for radionuclide therapy with <\u2009sup\u2009>\u2009177\u2009Lu-labelled PSMA-ligands (<\u2009sup\u2009>\u2009177\u2009Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46(12):2536\u201344. https:\/\/doi.org\/10.1007\/s00259-019-04485-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"7661_CR25","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2967\/jnumed.117.194209","volume":"59","author":"H Rathke","year":"2018","unstructured":"Rathke H, Giesel FL, Flechsig P, et al. Repeated\u2009<\u2009sup\u2009>\u2009177\u2009Lu-Labeled PSMA-617 radioligand therapy using treatment activities of up to 9.3 GBq. J Nucl Med. 2018;59(3):459\u201365. https:\/\/doi.org\/10.2967\/jnumed.117.194209.","journal-title":"J Nucl Med"},{"issue":"4","key":"7661_CR26","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/1754-9485.12891","volume":"63","author":"R McBean","year":"2019","unstructured":"McBean R, O\u2019Kane B, Parsons R, Wong D. Lu177-PSMA therapy for men with advanced prostate cancer: initial 18 months experience at a single Australian tertiary institution. J Med Imaging Radiat Oncol. 2019;63(4):538\u201345. https:\/\/doi.org\/10.1111\/1754-9485.12891.","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"1","key":"7661_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.clgc.2018.09.014","volume":"17","author":"L Emmett","year":"2019","unstructured":"Emmett L, Crumbaker M, Ho B, et al. Results of a prospective phase 2 pilot trial of <\u2009sup\u2009>\u2009177\u2009Lu-PSMA-617 therapy for metastatic Castration-Resistant prostate cancer including imaging predictors of treatment response and patterns of progression. Clin Genitourin Cancer. 2019;17(1):15\u201322. https:\/\/doi.org\/10.1016\/j.clgc.2018.09.014.","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"7661_CR28","doi-asserted-by":"publisher","first-page":"e8921","DOI":"10.7759\/cureus.8921","volume":"12","author":"M Sun","year":"2020","unstructured":"Sun M, Niaz MO, Nelson A, Skafida M, Niaz MJ. Review of 177Lu-PSMA-617 in patients with metastatic Castration-Resistant prostate cancer. Cureus. 2020;12(6):e8921. https:\/\/doi.org\/10.7759\/cureus.8921.","journal-title":"Cureus"},{"issue":"4","key":"7661_CR29","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.eururo.2024.09.020","volume":"87","author":"YH Dai","year":"2025","unstructured":"Dai YH, Chen PH, Lee DJ, Andrade G, Vallis KA. A meta-analysis and meta-regression of the efficacy, toxicity, and quality of life outcomes following prostate-specific membrane antigen radioligand therapy utilising Lutetium-177 and Actinium-225 in metastatic prostate cancer. Eur Urol. 2025;87(4):398\u2013408.","journal-title":"Eur Urol"},{"issue":"10276","key":"7661_CR30","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3.","journal-title":"Lancet"},{"issue":"1","key":"7661_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","volume":"25","author":"MS Hofman","year":"2024","unstructured":"Hofman MS, Emmett L, Sandhu S, TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group, et al. Overall survival with [<\u2009sup\u2009>\u2009177\u2009Lu]Lu-PSMA-617 versus Cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 2024;25(1):99\u2013107. https:\/\/doi.org\/10.1016\/S1470-2045(23)00529-6.","journal-title":"Lancet Oncol"},{"issue":"16","key":"7661_CR32","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.3390\/cancers13164017","volume":"13","author":"D Groener","year":"2021","unstructured":"Groener D, Baumgarten J, Haefele S, et al. Salvage radioligand therapy with repeated cycles of <\u2009sup\u2009>\u2009177\u2009Lu-PSMA-617 in metastatic Castration-Resistant prostate cancer with diffuse bone marrow involvement. Cancers (Basel). 2021;13(16):4017. https:\/\/doi.org\/10.3390\/cancers13164017.","journal-title":"Cancers (Basel)"},{"key":"7661_CR33","unstructured":"https:\/\/www.aifa.gov.it\/documents\/20142\/961234\/Determina_241-2025_Pluvicto.pdf"},{"issue":"5","key":"7661_CR34","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s00259-018-4222-x","volume":"46","author":"A Yordanova","year":"2019","unstructured":"Yordanova A, Linden P, Hauser S, et al. Outcome and safety of Rechallenge [<\u2009sup\u2009>\u2009177\u2009Lu]Lu-PSMA-617 in patients with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46(5):1073\u201380. https:\/\/doi.org\/10.1007\/s00259-018-4222-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"7661_CR35","doi-asserted-by":"publisher","first-page":"12477","DOI":"10.18632\/oncotarget.7245","volume":"7","author":"H Ahmadzadehfar","year":"2016","unstructured":"Ahmadzadehfar H, Eppard E, K\u00fcrpig S, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7(11):12477\u201388. https:\/\/doi.org\/10.18632\/oncotarget.7245.","journal-title":"Oncotarget"},{"issue":"5","key":"7661_CR36","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett L, Subramaniam S, Crumbaker M, ENZA-p Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2024;25(5):563\u201371. https:\/\/doi.org\/10.1016\/S1470-2045(24)00135-9.","journal-title":"Lancet Oncol"},{"issue":"4","key":"7661_CR37","doi-asserted-by":"publisher","first-page":"574","DOI":"10.2967\/jnumed.122.264456","volume":"64","author":"K Rahbar","year":"2023","unstructured":"Rahbar K, Essler M, Pabst KM, et al. Safety and survival outcomes of <\u2009sup\u2009>\u2009177\u2009Lu-Prostate-Specific membrane antigen therapy in patients with metastatic Castration-Resistant prostate cancer with Prior\u2009<\u2009sup\u2009>\u2009223\u2009Ra treatment: the RALU study. J Nucl Med. 2023;64(4):574\u20138. https:\/\/doi.org\/10.2967\/jnumed.122.264456.","journal-title":"J Nucl Med"},{"issue":"5","key":"7661_CR38","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2967\/jnumed.120.251017","volume":"62","author":"MJ Zacherl","year":"2021","unstructured":"Zacherl MJ, Gildehaus FJ, Mittlmeier L, et al. First clinical results for PSMA-Targeted \u03b1-Therapy Using\u2009<\u2009sup\u2009>\u2009225\u2009Ac-PSMA-I&T in Advanced-mCRPC patients. J Nucl Med. 2021;62(5):669\u201374. https:\/\/doi.org\/10.2967\/jnumed.120.251017.","journal-title":"J Nucl Med"},{"issue":"12","key":"7661_CR39","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2967\/jnumed.116.178673","volume":"57","author":"C Kratochwil","year":"2016","unstructured":"Kratochwil C, Bruchertseifer F, Giesel FL, et al. 225Ac-PSMA-617 for PSMA- targeted \u03b1-Radiation therapy of metastatic Castration-Resistant prostate cancer. J Nucl Med. 2016;57(12):1941\u20134. https:\/\/doi.org\/10.2967\/jnumed.116.178673.","journal-title":"J Nucl Med"},{"issue":"3","key":"7661_CR40","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00259-019-04612-0","volume":"47","author":"F Khreish","year":"2020","unstructured":"Khreish F, Ebert N, Ries M. 225Ac-PSMA-617\/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging. 2020;47(3):721\u20138. https:\/\/doi.org\/10.1007\/s00259-019-04612-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7661_CR41","doi-asserted-by":"crossref","unstructured":"Morris MJ et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet, 404, Issue 10459, 1227\u201339.","DOI":"10.1016\/S0140-6736(24)01653-2"},{"key":"7661_CR42","doi-asserted-by":"publisher","first-page":"102699","DOI":"10.1016\/j.ctrv.2024.102699","volume":"125","author":"EF Giunta","year":"2024","unstructured":"Giunta EF, Brighi N, Gurioli G, Matteucci F, Paganelli G, De Giorgi U. 177Lu-PSMA therapy in metastatic prostate cancer: an updated review of prognostic and predictive biomarkers. Cancer Treat Rev. 2024;125:102699. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102699.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"7661_CR43","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1053\/j.semnuclmed.2016.07.004","volume":"66","author":"V Murthy","year":"2025","unstructured":"Murthy V, Ludwig V, Gafita A, Hope TA, Calais J. The role of PSMA PET parameters as biomarkers for response to PSMA-Targeted radiopharmaceutical therapy. J Nucl Med. 2025;66(6):833\u20138. https:\/\/doi.org\/10.1053\/j.semnuclmed.2016.07.004.","journal-title":"J Nucl Med"},{"issue":"6","key":"7661_CR44","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1053\/j.semnuclmed.2016.07.004","volume":"46","author":"H Jadvar","year":"2016","unstructured":"Jadvar H. Is there use for FDG-PET in prostate cancer? Semin Nucl Med. 2016;46(6):502\u20136. https:\/\/doi.org\/10.1053\/j.semnuclmed.2016.07.004.","journal-title":"Semin Nucl Med"},{"key":"7661_CR45","doi-asserted-by":"publisher","unstructured":"Buteau JP, Martin AJ, Emmett L, TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [<\u2009sup\u2009>\u2009177\u2009Lu]Lu- PSMA-617 versus Cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol;23(11):1389\u201397. https:\/\/doi.org\/10.1016\/S1470-2045(22)00605-2","DOI":"10.1016\/S1470-2045(22)00605-2"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07661-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07661-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07661-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:26:21Z","timestamp":1774401981000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07661-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7661"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07661-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The approval was granted by the Ethics Committee of IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d and Area Vasta Romagna (CEROM).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study. All research participants provided informed consent for publication of their data and images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\u00a0and consent to publish"}},{"value":"The Authors have no relevant financial or non-financial interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}